Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ”

Merck & Co., Inc. (NYSE:MRK) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. It was one of the stocks mentioned in Cramer’s game plan, as he remarked:

Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its cancer portfolio after the 2026 American Society of Clinical Oncology Conference. That’s the most important cancer confab of the year. Merck’s cancer dominance has been challenged of late by JNJ. Let’s see what Merck has to say.

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions. A caller asked about the stock during the May 1 episode, and Cramer responded:

Okay, I thought Merck got, you know what, Merck reported a really good quarter, and it just happened on a day when people didn’t like pharma, and they didn’t like healthcare. And Rob Davis did a good job. The stock’s starting to come back. It was up $3 today. I think it can manage its way, all the way back to $120. I think you do good homework.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1